It is well documented that persons with acquired hemophilia may require treatment with the same clotting factor concentrates that are used to treat persons with inherited hemophilia complicated by inhibitors. Failure to provide adequate reimbursement for these coagulation therapies may adversely impact patient care, morbidity, and mortality. Thus, the Medical and Scientific Advisory Council of the National Hemophilia Foundation recommends that reimbursement for clotting factor concentrates for persons with acquired hemophilia be the same as for persons with congenital hemophilia with inhibitors.